Condition: Non Small Cell Lung Carcinoma · Sponsor: AbbVie
Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan r…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic Hospital - Phoenix /ID# 272971 | Phoenix, Arizona, United States | Active Not Recruiting |
| Providence - St. Jude Medical Center /ID# 271414 | Fullerton, California, United States | Recruiting |
| FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450 | Oxnard, California, United States | Recruiting |
| UCLA - Santa Monica /ID# 271690 | Santa Monica, California, United States | Recruiting |
| University Of Colorado - Anschutz Medical Campus /ID# 269069 | Aurora, Colorado, United States | Recruiting |
| Rocky Mountain Cancer Centers - Lone Tree /ID# 272603 | Lone Tree, Colorado, United States | Recruiting |
| Mayo Clinic Hospital Jacksonville /ID# 275073 | Jacksonville, Florida, United States | Recruiting |
| Mid Florida Hematology And Oncology Center /ID# 273777 | Orange City, Florida, United States | Recruiting |
| Hope And Healing Cancer Services /ID# 276223 | Hinsdale, Illinois, United States | Recruiting |
| Parkview Comprehensive Cancer Center /ID# 271879 | Fort Wayne, Indiana, United States | Recruiting |
| Community Health Network /ID# 273437 | Indianapolis, Indiana, United States | Completed |
| Kansas City Cancer Center /ID# 273679 | Overland Park, Kansas, United States | Recruiting |
+ 103 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06772623